Treace Medical Concepts, Inc. · NASDAQ:TMCI
Treace Medical Concepts — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
20 slides from Treace Medical Concepts's conference presentation, Jan 13, 2026
Slide 1: 44th Annual J.P. Morgan Healthcare Conference
1 44th Annual J.P. Morgan Healthcare Conference John T. Treace, CEO, Founder, Chairman January 14, 2026
Slide 2: Forward-looking Statements
Forward-looking Statements: This presentation and our Q&A session may include forward-looking statements subject to substantial risks and uncertainties that may cause actual results to differ materially from those anticipated or implied by such forward-looking statements. We include forward-looking
Slide 3: Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc. Medical Device Company Focused on the surgical treatment of bunions and related deformities Industry’s Only Bunion Focused Direct Sales Team Market Leading Technology protected by 96 US Patents and 84 US Pending Patents Driving Penetration FY 2025 preliminary revenue of
Slide 4: Largest & Most Underpenetrated Segment in Foot & Ankle
Largest & Most Underpenetrated Segment in Foot & Ankle 4.4M 1.1M 450K Bunion Patient Opportunity ~10,000 Surgeons ~1 in 4 adults in the US affected1 67M Surgical Procedures3 $2.3B Current US Market Surgical Candidates $5B+ US Market Opportunity Seek Medical Treatment Annually2 Americans Affected (1)
Slide 5: Bunions: 3-Plane Deformities
Transverse Plane Sagittal Plane Frontal Plane Bunions: 3-Plane Deformities 5 An unstable joint in the middle of the foot allows the metatarsal bone to shift outward… creating the painful “bump” on the side of the big toe Bunion (bump) presents here Unstable joint is here In nearly 90% of bunions, th
Slide 6: Lapiplasty: The Gold Standard for 3-Plane Correction
Lapiplasty®: The Gold Standard for 3-Plane Correction 6 Treace has democratized a 3D Lapidus bunion procedure, making it accessible to more surgeons and their patients Correct. Fixate. Cut. Compress. The Patented Lapiplasty® Procedure
Slide 7: 4-Year Published Prospective, Multicenter Lapiplasty Results
Patient Reported Outcomes (Mean) Visit MOxFQ and VAS Pain Scores Over Time ALIGN3D™ Multicenter Prospective Study1 7 centers, 13 surgeons, 173 patients treated (139 at 48-month follow up) Compelling Outcomes Supported by Differentiated Clinical Data The only commercial surgical bunion system support
Slide 8: Driving penetration of our comprehensive 3D bunion portfolio
Driving penetration of our comprehensive 3D bunion portfolio Accelerating our bunion procedure volume growth Expanding our offerings to build wallet share Micro-Lapiplasty® Mini-Adductoplasty™ SpeedMTP® Percuplasty™ IntelliGuide® PSI Nanoplasty® Lapiplasty® Lightning™ 2026 Pioneering the Future of 3
Slide 9: Comprehensively Addressing All Bunion Classes
Mild to Moderate Moderate to Severe w/ Midfoot Deformity w/ Arthritic Great Toe Joint Comprehensively Addressing All Bunion Classes 9 Extending our leadership through targeted best-in-class 3D instrumented systems 70% of Bunion Surgeries1 30% of Bunion Surgeries1 Present2 in ~ 30% Present3 in ~20% (
Slide 10: Comprehensively Addressing All Bunion Classes
Mild to Moderate Moderate to Severe w/ Midfoot Deformity w/ Arthritic Great Toe Joint Comprehensively Addressing All Bunion Classes 10 Extending our leadership through targeted best-in-class 3D instrumented systems 70% of Bunion Surgeries1 30% of Bunion Surgeries1 Present2 in ~ 30% Present3 in ~20%
Slide 11: Expanding Patient Access to Bunion Surgery
Expanding Patient Access to Bunion Surgery Intelliguide™ PSI Micro-Lapiplasty® Lapiplasty® Of surgeons expect MIS osteotomies to be their fastest growing bunion procedure in the next year* 58% Traditional Open Osteotomy Percuplasty™ Percutaneous 3D Correction 4.4M Seeking Medical Treatment1 1.1M Sur
Slide 12: Expanding the Bunion Market Through Minimally Invasive Approaches
12 Percuplasty™ Percutaneous 3D Bunion Correction Percuplasty™ MIS Power System* Plug & Play MIS Burr Pre-Settings Nanoplasty® 3D MIS Bunion Correction Accelerating Surgeon Access to 3D MIS Bunion Surgery Expanding the Bunion Market Through Minimally Invasive Approaches *Third-party manufactured and
Slide 13: Advancing Our Leadership in Lapiplasty Technology
13 Advancing Our Leadership in Lapiplasty® Technology Lapiplasty® Lightning™ Next-Generation Instrumentation IntelliGuide® PSI Patient-Specific 3D Bunion Correction SpeedTMT™ Rapid Compression Implant 5th generation instrumentation Less steps, faster procedure Enhanced control of 3D correction Fast
Slide 14: Expanding Offerings for Our Growing Customer Base
Expanding Offerings for Our Growing Customer Base 14 Cortifuse™ Demineralized Cortical Fibers SpeedMTP® SpeedAkin™ MicroQuad™ Allograft Wedges SpeedPlate® Implants Complementary Biologics1 Sterile Instruments Percuplasty™ SuperBite™ 1Third party manufactured and distributed by Treace. COMING 2026 NE
Slide 15: Go-to-Market Strategy
Go-to-Market Strategy (1) Sales reps and field fleet includes W2 employees and FTE 1099 sales agents, as of December 31, 2025 Comprehensive introductory and advanced events with experienced surgeon faculty Hands-on training events Focused Surgeon Education Bunion-focused sales force helps drive deep
Slide 16: Market-Capturing Momentum
Market-Capturing Momentum A Step Ahead™ 16 Tom Lapiplasty® patient All Bunion Cases (~450k annual U.S. cases) Total Penetration3 2.5% 5.5% 7.8% 6.6% 3.9% 2025 2023 2021 21% 5-year CAGR¹ in Active Surgeons2 33% Treace bunion procedures of U.S. bunion surgeons using Active Surgeons2 (~10,000 U.S. Surg
Slide 17: Meaningful leverage opportunities to drive profitability
Meaningful leverage opportunities to drive profitability Continued focus on operating expense leverage & management Scalability of business Technology-enabled efficiencies 17 Focus on Improved Profitability 4Q’25E 2 We again expect to deliver positive Adj. EBITDA in Q4 The Company defines Non-GAAP a
Slide 18: Now a comprehensive bunion solutions company with multiple new technologies
Now a comprehensive bunion solutions company with multiple new technologies Positioned to deliver continued procedure volume growth in 2026 and beyond Strong R&D pipeline of technologies for 2026 and beyond The Leader in the largest and most underpenetrated segment of the foot and ankle market¹ Mult
Slide 19: The Leader in 3D Bunion Correction
19 The Leader in 3D Bunion Correction®
Slide 20: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations 20
Treace Medical Concepts — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix